SG11202104864QA - Multispecific binding constructs against checkpoint molecules and uses thereof - Google Patents

Multispecific binding constructs against checkpoint molecules and uses thereof

Info

Publication number
SG11202104864QA
SG11202104864QA SG11202104864QA SG11202104864QA SG11202104864QA SG 11202104864Q A SG11202104864Q A SG 11202104864QA SG 11202104864Q A SG11202104864Q A SG 11202104864QA SG 11202104864Q A SG11202104864Q A SG 11202104864QA SG 11202104864Q A SG11202104864Q A SG 11202104864QA
Authority
SG
Singapore
Prior art keywords
multispecific binding
binding constructs
checkpoint molecules
constructs against
against checkpoint
Prior art date
Application number
SG11202104864QA
Inventor
Bing Gong
Rachel Rennard
Amanda Oliphant
Cheuk Leung
Benjamin Wolf
Ugur Eskiocak
Pearl Bakhru
Diana Albu
Original Assignee
Compass Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Therapeutics Llc filed Critical Compass Therapeutics Llc
Publication of SG11202104864QA publication Critical patent/SG11202104864QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202104864QA 2018-11-13 2019-11-13 Multispecific binding constructs against checkpoint molecules and uses thereof SG11202104864QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862760801P 2018-11-13 2018-11-13
US201962855580P 2019-05-31 2019-05-31
US201962898991P 2019-09-11 2019-09-11
US201962931478P 2019-11-06 2019-11-06
PCT/US2019/061226 WO2020102387A1 (en) 2018-11-13 2019-11-13 Multispecific binding constructs against checkpoint molecules and uses thereof

Publications (1)

Publication Number Publication Date
SG11202104864QA true SG11202104864QA (en) 2021-06-29

Family

ID=70731958

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104864QA SG11202104864QA (en) 2018-11-13 2019-11-13 Multispecific binding constructs against checkpoint molecules and uses thereof

Country Status (12)

Country Link
US (2) US11046769B2 (en)
EP (1) EP3880716A4 (en)
JP (1) JP7497351B2 (en)
KR (1) KR20210107628A (en)
CN (1) CN113166269A (en)
AU (1) AU2019379576A1 (en)
BR (1) BR112021008795A2 (en)
CA (1) CA3119161A1 (en)
IL (1) IL283087A (en)
MX (1) MX2021005594A (en)
SG (1) SG11202104864QA (en)
WO (1) WO2020102387A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226984A1 (en) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody against pd-1 and pd-l1
CN113754773A (en) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 Bispecific antibody for resisting PD1 XPDL 1
WO2023193767A1 (en) * 2022-04-08 2023-10-12 上海济煜医药科技有限公司 Antigen binding protein and application thereof
CN116574192A (en) * 2023-03-30 2023-08-11 上海妙聚生物科技有限公司 Cytokine fusion protein capable of being conditionally released and activated, and preparation and application thereof

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4496654A (en) 1983-04-08 1985-01-29 Quidel Detection of HCG with solid phase support having avidin coating
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5026773A (en) 1987-03-11 1991-06-25 Samuel Steel Apparatus for a solid phase synthesis of peptide analogs
JPH021556A (en) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd Hybrid antibody and production thereof
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5071909A (en) 1989-07-26 1991-12-10 Millipore Corporation Immobilization of proteins and peptides on insoluble supports
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
DE59109273D1 (en) 1990-02-01 2010-01-07 Siemens Healthcare Diagnostics Production and Use of Genebanks of Human Antibodies ("Human Antibody Libraries")
CZ280777B6 (en) 1990-02-02 1996-04-17 Ústav Organické Chemie A Biochemie Avčr Process of multistep synthesis of peptides on planar carriers and apparatus for making the same
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR0185215B1 (en) 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
NL9101953A (en) 1991-11-21 1993-06-16 Seed Capital Investments TESTING DEVICE CONTAINING A PLATE WITH A MULTIPLE OF WELLS WITH AN ASSOCIATED DOSING DEVICE, AND A KIT INCLUDING THESE DEVICES AND USE OF THE DEVICES.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2135408A1 (en) 1992-05-08 1993-11-25 Peter C. Keck Chimeric multivalent protein analogues and methods of use thereof
US5287082A (en) 1992-07-02 1994-02-15 Cornell Research Foundation, Inc. Submicron isolated, released resistor structure
DK1087013T3 (en) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobulins without light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
JPH09506262A (en) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション Method for producing specific antibody
DE69534347T2 (en) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Libraries of polyclonal antibodies
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0827544B1 (en) 1995-05-23 2004-08-18 MorphoSys AG Multimeric proteins
ATE219517T1 (en) 1995-08-18 2002-07-15 Morphosys Ag PROTEIN/(POLY)PEPTIDE LIBRARIES
CN1173878A (en) 1995-10-16 1998-02-18 尤尼利弗公司 Bifunctional or bivalent antibody fragment analogue
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
PT1012280E (en) 1997-06-11 2005-02-28 Borean Pharma As TRIMMING MODULE
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
WO1999037791A1 (en) 1998-01-23 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Multipurpose antibody derivatives
CZ121599A3 (en) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Single-chain molecule binding several antigens, process of its preparation and medicament in which the molecule is comprised
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
PT1176195E (en) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
DE60033293D1 (en) 1999-08-23 2007-03-22 Dana Farber Cancer Inst Inc NEW B7-4 MOLECULES AND THEIR USES
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
CN1461344A (en) 2000-07-25 2003-12-10 免疫医疗公司 Multivalent target binding protein
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US20040242847A1 (en) 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
ATE498718T1 (en) 2000-12-18 2011-03-15 Dyax Corp DIRECTED LIBRARIES THAT ARE GENETICALLY PACKAGED
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002247826A1 (en) 2001-03-13 2002-09-24 University College London Specific binding members
DK1399484T3 (en) 2001-06-28 2010-11-08 Domantis Ltd Double-specific ligand and its use
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (en) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimeric, single chain, tandem Fv antibodies
US20030211078A1 (en) 2001-12-07 2003-11-13 Heavner George A. Pseudo-antibody constructs
JP4968498B2 (en) 2002-01-23 2012-07-04 ユニバーシティ オブ ユタ リサーチ ファウンデーション Targeted chromosomal mutagenesis using zinc finger nuclease
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
JP4386741B2 (en) 2002-04-15 2009-12-16 中外製薬株式会社 How to create scDb library
WO2003104415A2 (en) 2002-06-05 2003-12-18 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
PT2206517T (en) 2002-07-03 2023-11-07 Tasuku Honjo Immunopotentiating compositions comprising anti-pd-l1 antibodies
AU2003298574B2 (en) 2002-09-05 2008-04-24 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
EP1618181B1 (en) 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
WO2005035586A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
US20050136051A1 (en) 2003-12-22 2005-06-23 Bernard Scallon Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US7557197B2 (en) 2004-01-28 2009-07-07 Oregon Health & Science University Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
EP1751181B1 (en) 2004-06-02 2012-08-15 AdAlta Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc Novel tetravalent bispecific antibody
US20060040354A1 (en) 2004-07-20 2006-02-23 O'keefe Theresa L Novel polyadenylation signal for use in expression vectors
JP2008511337A (en) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド Heteromultimeric molecule
EP1848672A4 (en) 2005-02-01 2009-11-04 Morphosys Ag Libraries and methods for isolating antibodies
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
JP5011277B2 (en) 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド Methods and uses for generating stably linked complexes consisting of homodimers, homotetramers or dimeric dimers
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
EP1913149A4 (en) 2005-07-26 2009-08-05 Sangamo Biosciences Inc Targeted integration and expression of exogenous nucleic acid sequences
BRPI0615026A8 (en) 2005-08-19 2018-03-06 Abbott Lab double variable domain immunoglobulin and its uses
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602005018477D1 (en) 2005-08-26 2010-02-04 Pls Design Gmbh Bivalent IgY antibody constructs for diagnostic and therapeutic applications
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
CA2625619A1 (en) 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007062466A1 (en) 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
AU2007215013A1 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Functional antibodies
JP5374359B2 (en) 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド Stabilized polypeptide compounds
US9315578B2 (en) 2006-03-23 2016-04-19 Tohoku Univeristy High functional bispecific antibody
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
AR060070A1 (en) 2006-03-24 2008-05-21 Merck Patent Gmbh HETERODYMERIC PROTEIN DOMAINS OBTAINED BY ENGINEERING
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2799449A1 (en) 2006-05-25 2014-11-05 Bayer Intellectual Property GmbH Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2078040B1 (en) 2006-11-02 2017-06-28 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
CA2964398C (en) 2007-09-14 2023-03-07 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US7947495B2 (en) 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
US20110189203A1 (en) 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs
ES2614284T3 (en) 2007-11-30 2017-05-30 Glaxo Group Limited Antigen binding constructs
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009089295A2 (en) 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anti-hiv domain antibodies and method of making and using same
DE102008010362A1 (en) 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 as a therapeutic and diagnostic target for viral diseases
WO2009132287A2 (en) 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
US8735331B2 (en) 2008-09-10 2014-05-27 Philochem Ag Display library for antibody selection
PL2342226T3 (en) * 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102625848A (en) 2009-07-17 2012-08-01 生物蛋白有限公司 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
KR101930964B1 (en) 2010-04-20 2018-12-19 젠맵 에이/에스 Heterodimeric antibody fc-containing proteins and methods for production thereof
DK3336225T3 (en) 2010-07-16 2020-03-30 Adimab Llc ANTIBODY LIBRARIES
CN102760801B (en) 2011-04-29 2015-04-01 清华大学 Preparation method of light-emitting diode
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
EP3674320A3 (en) 2011-10-27 2020-08-12 Genmab A/S Production of heterodimeric proteins
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
KR102229873B1 (en) * 2012-10-12 2021-03-19 더 브리검 앤드 우먼즈 하스피털, 인크. Enhancement of the immune response
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
MX2015011095A (en) 2013-02-26 2016-03-11 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy.
RS60826B1 (en) 2013-07-16 2020-10-30 Hoffmann La Roche Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
BR112016015140A2 (en) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. tandem-fab immunoglobulin and its uses
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
ES2783026T3 (en) 2014-02-04 2020-09-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for the treatment of cancer
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
DK3149042T3 (en) 2014-05-29 2019-11-04 Spring Bioscience Corp PD-L1 antibodies and uses thereof
CN110964108B (en) 2014-08-05 2023-07-07 中美冠科生物技术（太仓）有限公司 anti-PD-L1 antibodies
JP6586454B2 (en) 2014-08-14 2019-10-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Combination therapy of an antibody that activates human CD40 and an antibody against human PD-L1
WO2016029073A2 (en) 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016030455A1 (en) 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
UY36351A (en) * 2014-10-14 2016-06-01 Novartis Ag ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
BR112017015136A2 (en) 2015-01-14 2018-01-30 Compass Therapeutics Llc multispecific immunomodulator antigen binding construct polypeptide, multispecific immunomodulator antigen binding construct, conjugate, pharmaceutical composition, method for treating an individual with cancer, method for inhibiting or reducing cancer growth, composition, cell, method of making a polypeptide of multispecific immunomodulatory antigen binding construct, vector or vector set and kit
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
US9861621B2 (en) 2015-06-29 2018-01-09 Biomed Valley Discoveries, Inc. LPT-723 and immune checkpoint inhibitor combinations and methods of treatment
CA2998589A1 (en) 2015-09-14 2017-03-23 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.
PE20181349A1 (en) 2015-10-07 2018-08-22 Hoffmann La Roche BIESPECIFIC ANTIBODIES WITH TETRAVALENCE FOR A CO-STIMULATING FNT RECEIVER
JP2019503349A (en) * 2015-12-17 2019-02-07 ノバルティス アーゲー Antibody molecules against PD-1 and uses thereof
AU2017207480A1 (en) 2016-01-13 2018-08-02 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
MX2018009581A (en) 2016-02-06 2019-05-06 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof.
CN109072191B (en) 2016-04-04 2024-03-22 苏黎世联邦理工学院 Mammalian cell lines for protein production and library generation
AR108377A1 (en) 2016-05-06 2018-08-15 Medimmune Llc BISPECIFIC UNION PROTEINS AND ITS USES
PE20190510A1 (en) 2016-06-13 2019-04-10 I Mab ANTI-PD-L1 ANTIBODIES AND USES OF THE SAME
KR102629905B1 (en) * 2017-04-01 2024-01-30 베이징 한미 파마슈티컬 컴퍼니 리미티드 Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
CN111094347A (en) * 2017-07-06 2020-05-01 美勒斯公司 Binding molecules that modulate biological activity expressed by cells
WO2020006605A1 (en) 2018-07-04 2020-01-09 Honeycomb Media Pty Ltd Method and system for providing incentives to users

Also Published As

Publication number Publication date
US11970538B2 (en) 2024-04-30
WO2020102387A1 (en) 2020-05-22
CN113166269A (en) 2021-07-23
EP3880716A1 (en) 2021-09-22
IL283087A (en) 2021-06-30
EP3880716A4 (en) 2022-08-03
AU2019379576A1 (en) 2021-06-03
MX2021005594A (en) 2021-10-22
JP2022507253A (en) 2022-01-18
US20200181266A1 (en) 2020-06-11
US20210284736A1 (en) 2021-09-16
KR20210107628A (en) 2021-09-01
CA3119161A1 (en) 2020-05-22
BR112021008795A2 (en) 2021-08-31
TW202031288A (en) 2020-09-01
JP7497351B2 (en) 2024-06-10
US11046769B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
IL277551A (en) Trispecific binding molecules against caners and uses thereof
IL274591A (en) Trispecific binding molecules against tumor-associated antigens and uses thereof
IL278959A (en) Binding molecules against bcma and uses thereof
IL275510A (en) Ror1-specific antigen binding molecules
IL283635A (en) Binding molecules against cd3 and uses thereof
IL281901A (en) Multivalent igm- and iga-fc-based binding molecules
IL254223A (en) Cd20 binding molecules and uses thereof
PT3583129T (en) Cd70 binding molecules and methods of use thereof
IL266464A (en) Binding molecules specific for asct2 and uses thereof
IL283087A (en) Multispecific binding constructs against checkpoint molecules and uses thereof
ZA201806597B (en) Ilt7 binding molecules and methods of using the same
HK1253092A1 (en) Neutralizing anti-influenza binding molecules and uses thereof
GB201702091D0 (en) Specific binding molecules
IL289415A (en) Claudin-6 binding molecules and uses thereof
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
IL278832A (en) Optimized gp41-binding molecules and uses thereof
IL269752B (en) Fgfr3 binding molecules